Navigation Links
Applied Genetics Initiates Commercial Operation
Date:6/25/2012

WESTMINSTER, Colo., June 25, 2012 /PRNewswire/ -- GeneThera Inc. (OTCQB: GTHR) is pleased to announce that Applied Genetics, GeneThera's majority owned subsidiary, has initiated commercial operation of its molecular diagnostic laboratory based in Monterrey, Mexico. Applied Genetics molecular diagnostic laboratory is the first molecular laboratory in Mexico, to date, which is capable to detect Johne's disease at the molecular level in milk, blood, and feces from dairy cows, goats and sheep infected with the disease using state-of-the-art molecular technology. Applied Genetics utilizes GeneThera proprietary Johne's disease HerdCheck™ Field Collection System (FCS) Molecular Assay. Dr. Tony Milici, interim president of Applied Genetics and CEO of GeneThera, stated; "The starting of Applied Genetics commercial operation is a great success for GeneThera.  I think it is pretty remarkable that we were able to accomplish our goal in less than 18 months. This achievement was made possible thanks to the commitment and dedication of the Company's management and the outstanding support of our loyal investors and collaborators. I have to thank deeply all the people who believed in the Company and its ability to achieve its goals; I am grateful." 

Nutrition Avanzada, GeneThera's exclusive buyer and distributor of the proprietary Johne's disease molecular system in Mexico, has entered into an agreement with a large veterinary laboratory in Northern Mexico. This agreement will provide access to about 20,000 animals initially. These animals will be tested for the presence of mycobacterium paratuberculosis in milk, blood and feces.  Positive animals will be tested every 3 months to monitor progress of the disease. The cost of the test will range from US $30.00 – $32.00. In addition, Nutrition Avanzada is in the final negotiation stages with two of the largest dairy companies in Mexico.

As previously announced Nutricion Avanzada will purchase the Johne's disease Field Collection System kit from Applied Genetics and resell it directly to third parties. Samples will be then shipped to Applied Genetics laboratory for processing.  The commercial operation will be implemented in Three (3) Phases: during the current initial Phase (Phase I), Applied Genetics target is to process a maximum of 100 samples/daily. Phase II, to be initiated in late fall of 2012, will increase Applied Genetics sample process throughput to 1500 samples/daily. Phase II will be implemented in the early part of 2013, which will further increase sample throughput to over 2000 samples daily.

Johne's disease is a global devastating and incurable disease of dairy cows, sheep and goats caused by a bacterium called Mycobacterium Paratuberculosis sub. Avium, (MAP).  Dairy products, contaminated with MAP, are the vehicles by which the infection spreads in the human intestine triggering the onset of Crohn's disease. Applied Genetics employs the use of GeneThera HerdCheck™ to test and control the spread of Johne's disease in Mexico.  HerdCheck™ is a proprietary molecular diagnostic system based on the use of high throughput robotics and Real time PCR.

About GeneThera, Inc.

GeneThera, Inc. is a molecular biotechnology company located in Westminster, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression system, GES™ and Johne's disease management system, HERDCHECK™ designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES™ and HERDCHECK™ systems are designed for a host of individual diseases, the current priority being Johne's disease. For more information, contact Dr. Tony Milici at 720-439-3011. http://www.genethera.net

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

GeneThera, Inc

 


'/>"/>
SOURCE GeneThera, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Thomas Elsaesser and Horst Weller receive the Julius Springer Prize for Applied Physics 2012
2. GeneThera, Inc. Acquires Applied Genetics, S.A.
3. iBioLaunch™ Technology Successfully Applied to Modified C1 Inhibitor
4. Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement for Next-Gen Sequencing Software Tools
5. JS Genetics announces launch of XCAT-KS, a bloodless, cheek swab test for the diagnosis of Klinefelter syndrome and other Male sex chromosome aneuploidies
6. Khan Academy and 23andMe Partner to Promote Genetics Education on DNA Day
7. Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team
8. Genetics Policy Institute (GPI) Files Additional Legal Arguments in Sherley v. Sebelius Stem Cell Case
9. deCODE Genetics, in Collaboration with Academic Colleagues, Discovers Three Variants in the Sequence of the Human Genome that Affect the Risk of Thyroid Cancer
10. Cytogenetics - Technologies, Markets and Companies
11. Ambry Genetics Launches Illumina MiSeq Next-Gen Sequencing Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... , ... Intelligent Implant Systems announced today that the two-level components for the ... United States. These components expand the capabilities of the system and allow Revolution™ ... October of 2015, the company has seen significant sales growth in 1Q 2016, and ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... will deliver a talk on its first-in-class technologies for tissue stem cell counting ... on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome Engineering in Burlington, Massachusetts. ...
(Date:4/27/2016)... ... ... The Pittcon Organizing Committee is pleased to announce that Charles “Chuck” Gardner was named ... 1987. Since then, he has served in a number of key leadership positions including ... program and exposition committees. In his professional career, Dr. Gardner is the director of ...
(Date:4/27/2016)... ... 27, 2016 , ... NDA Partners Chairman Carl Peck, ... Expert Consultant. Mr. Clark was formerly a Vice President with US Pharmacopeia, ... molecule monographs based on analytical methods. NDA Partners Expert Consultants are top ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
Breaking Biology News(10 mins):